Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

HIV Infections Clinical Trial

Official title:

Evaluation of the Epidermal Langerhans Cell Population in AIDS / ARC Patients by the Topical Application of a Potent Contact Allergen (1-Chloro-2,4-Dinitro-Chlorobenzene) (DNCB)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00002031
• Other study ID #: 047A
• Status: Completed
• Phase: N/A
• First received: November 2, 1999
• Last updated: June 23, 2005

Study information

• Verified date: February 1990
• Source: NIH AIDS Clinical Trials Information Service
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To evaluate the effect of application of Dinitrochlorobenzene (DNCB) on the number, morphology, and antigen expression of epidermal Langerhans cells in AIDS and AIDS related complex (ARC) patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria

Patients must have the following:

• Stage III or IV HIV infection.

• Provide informed consent.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

• Kaposi's sarcoma lesions in the proposed treatment sites.

• Liable to require radiation or chemotherapy during the course of the study.

• Not likely to survive the length of the study.

• Obvious ultra-violet-irradiated skin damage in the treatment areas and anyone with recent UV exposure or likely to have such exposure (e.g.:

• holiday tans obtained in Hawaii, members of UV box tanning salons, etc.) Allergy to lidocaine.

Concurrent Medication:

Excluded:

• Other Immunomodulators.

Concurrent Treatment:

Excluded:

• Radiation.

Patients with the following are excluded:

• Kaposi's sarcoma lesions in the proposed treatment sites.

• Liable to require radiation or chemotherapy during the course of the study.

• Not likely to survive the length of the study.

• Obvious ultra-violet-irradiated skin damage in the treatment areas.

• Allergy to lidocaine.

Prior Medication:

Excluded:

• Prior DNCB therapy.

Study Design

Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV Infections

Intervention

Drug:
• Dinitrochlorobenzene

Locations

Country	Name	City	State
United States	San Francisco AIDS Clinic / San Francisco Gen Hosp	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

References & Publications (1)

Stricker RB, Elswood BF. Dendritic cells and dinitrochlorobenzene (DNCB): a new treatment approach to AIDS. Immunol Lett. 1991 Aug;29(3):191-6. Review. Erratum in: Immunol Lett 1992 Aug;33(3):316. — View Citation